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accepted August 2troke prevention in patients with atrial ﬁbrillation is a growing clinical dilemma as the incidence of the arrhythmia
increases and risk proﬁles worsen. Strategies in patients with nonvalvular atrial ﬁbrillation have included
anticoagulation with a variety of drugs. Knowledge that stroke in this setting typically results from thrombus in the
left atrial appendage has led to the development of mechanical approaches, both catheter-based and surgical, to
occlude that structure. Such a device, if it were safe and effective, might avoid the need for anticoagulation and
prevent stroke in the large number of patients who are currently not treated with anticoagulants. Regulatory
approval has been difﬁcult due to trial design challenges, balance of the risk-beneﬁt ratio, speciﬁc patient
populations studied, selection of treatment in the control group, and speciﬁc endpoints and statistical analyses
selected. Accumulating data from randomized trials and registries with longer-term follow-up continues to support
a role for left atrial appendage exclusion from the central circulation as an alternative to anticoagulation in carefully-
selected patient populations. (J Am Coll Cardiol 2014;63:291–8) ª 2014 by the American College of Cardiology
FoundationBy virtue of its increasing incidence and the increased
potential for embolic stroke, atrial ﬁbrillation (AF) is among
the most complex and difﬁcult challenges in the ﬁeld of
modern cardiovascular disease, and it represents a major
health concern (1–5). The projected number of patients in
the United States will be approximately 10 million by 2050
(3). In the setting of nonvalvular AF, two-thirds of strokes
are cardioembolic. Echocardiographic and pathologic studies
suggest that when a source can be identiﬁed, approximately
90% of such strokes can be attributed to thrombus in the left
atrial appendage (LAA) (6).
The relationship between the increased burden of AF
with advancing age and the increased incidence of related
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7, 2013.concern because of the attendant increased mortality and
morbidity from AF-related stroke; cardioembolic strokes are
particularly catastrophic, resulting in the worst prognosis
among the various causes of stroke (1,7–9). The search for
strategies to prevent or at least decrease stroke frequency in
this setting has drawn considerable attention; this review
provides an overview of these strategies with a focus on
nonpharmacological approaches.Risk Prediction Models
Prediction of stroke. Models for prediction of stroke risk
most commonly have relied on clinical variables (10–14).
Evaluation and comparison of multiple models have docu-
mented relatively poor performance, with inability to predict
central nervous system events. In a study of 79,884 patients
followed for an average of 4 years, risk prediction models
were found to have only modest discriminatory ability, with
C-statistics of approximately 0.60 (12). The most commonly
used model has been CHADS2 (congestive heart failure,
hypertension, age 75 years, diabetes mellitus, stroke/tran-
sient ischemic attack) score (Table 1), although this has
now been largely supplanted by the CHA2DS2 VASC
(CHADS2 plus vascular disease, age 65 to 74 years, and
female sex) score (Table 1), which has the advantage of
discriminating the potential for stroke in lower-risk patient
groups, and thereby might facilitate the selection of
preventive strategies that are more speciﬁc (11,12).
Prediction of bleeding risk. A variety of bleeding risk
scores have also been developed. Recently, 3 scoring systems
Table 1 CHADS2 Scores
CHADS2 Score
Risk Factor Score
CHF 1
Hypertension 1
Age 75 yrs 1
Diabetes mellitus 1
Stroke/TIA 2
Two commonly used scores for risk predict
tion. With these scores, there is an increase
score.
CHADS2 ¼ congestive heart failure, hyp
transient ischemic attack; CHA2DS2 VASC
and female sex; CHF ¼ congestive heart fail
Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CI = conﬁdence interval
INR = international
normalized ratio(s)
LAA = left atrial appendage
NOAC = novel oral
anticoagulant
RR = rate ratio
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292have been evaluated in patients
with AF (15). These included
ATRIA (anticoagulation and risk
factors in AF), HEMORR2HA-
GES (hepatic or renal disease,
ethanol abuse, malignancy, older
age, reduced platelet count or
function, rebleeding, hyperten-
sion, anemia, genetic factors, ex-
cessive fall risk, and stroke),
and HAS-BLED (hypertension,
abnormal renal/liver function,stroke, bleeding history or pre-disposition, labile interna-
tional normalized ratio [INR],>65 years, drug or alcohol use)
(15). The latter score has become perhaps the most widely
used. When applied in 2,293 patients with AF who were
randomized to either ﬁxed-dose Idraparinux (sanoﬁ-aventis,
Bridgewater, New Jersey) or adjustable-dose oral vitamin K,
the HAS-BLED score performed best in predicting any
clinically-relevant bleeding. In addition, the HAS-BLED
score was the only one that demonstrated signiﬁcant predic-
tion for intracranial hemorrhage. However, all 3 scores
demonstrated only modest performance in predicting any
clinically-relevant bleeding, with C-indexes below 0.70 (15).
Anticoagulant therapy. Anticoagulant therapy has been
the mainstay of therapy for stroke prevention in AF (1,16–24).
Limited initially to warfarin, several important observations
and conclusions have been drawn. Although warfarin
therapy is very effective in reducing ischemic stroke (in
contrast to acetylsalicylic acid, which has very limited
effectiveness), several issues with it have been identiﬁed
(1,24–31):
1. Less than 50% of patients at risk for stroke are
prescribed or ﬁll a prescription for warfarin on
presentation with AF. This relates to several factors,
including patient preference and real or perceived
relative or absolute contraindications that are typically
related to concerns for bleeding hazard (9,28–30).CHA2DS2 VASC Score
Risk Factor Score
CHF/LF dysfunction 1
Hypertension 1
75 yrs 2
Diabetes mellitus 1
Stroke/TIA 2
Vascular disease 1
65–74 yrs 1
Female sex 1
ion of stroke in patients with nonvalvular atrial ﬁbrilla-
in the incidence of stroke with an increasing additive
ertension, age 75 years, diabetes mellitus, stroke/
¼ CHADS2 plus vascular disease, age 65 to 74 years,
ure; LF ¼ labile factor; TIA ¼ transient ischemic attack.2. Of those patients prescribed warfarin, there is ongoing
attrition of its use to approximately 40% by 4 years
(31).
3. During periods where warfarin must be withheld, such
as for surgery or signiﬁcant bleeding, patients are
exposed to a window of thromboembolic risk.
4. Variable control of INR is frequent, with only app-
roximately 60% of serial INR in randomized clinical
trials being within therapeutic range (24–27,32).
5. There is patient inconvenience and cost with long-
term monitoring of INR, dose adjustments, and
multiple drug-to-drug interactions.
6. The risk of bleeding is increased when warfarin is
administered along with dual antiplatelet therapy for
associated conditions such as drug-eluting stents
(33–35). When bleeding occurs in this setting, both
warfarin and the dual antiplatelet therapy may be
withheld, increasing the risk of stent thrombosis.
Because of these issues, novel oral anticoagulants
(NOACs) have been developed and tested in large-scale
randomized clinical trials in aggregate enrolling >50,000
patients (36–43) (Table 2). Although most studies with
NOACs have shown them to be either noninferior or
superior to warfarin for stroke reduction, bleeding rates have
been somewhat variable. Compared with warfarin, both
factor Xa inhibitors and 2 doses of the direct thrombin
inhibitor dabigatran showed a large reduction in hemor-
rhagic strokes (36–44). Major bleeding rates with these
agents, however, still exceeded 2% to 3% per year, and minor
bleeding rates were over 10% per year (36). Thus, although
improved, hemorrhagic complications remain a signiﬁcant
and serious limitation of new oral anticoagulants. When
major bleeding occurs, it is associated with increased risk of
death that, although less than with warfarin, is still
substantial. As previously mentioned, a major complication
with bleeding is that it often leads to discontinuation of
antithrombotic therapy at least until the bleeding risk is
minimized, leaving the patient exposed to the underlying
thromboembolic risk. Consequently, within 2 years
of initiating therapy with NOACs, approximately 20% of
patients have discontinued them (36). One advantage
of the NOACs is that they do not require monitoring, which
makes them more clinically acceptable than warfarin, but
this paradoxically limits the physician’s ability to ensure
patient compliance, particularly with the short half-lives of
these NOACs. Furthermore, the lack of widely available
antagonists renders management problematic when emer-
gency surgical procedures are necessary or when bleeding
occurs.
There are no direct head-to-head trials comparing the
NOACs. A recent meta-analysis (40) included 44,733
patients from 4 studies that included apixaban, dabigatran,
and rivaroxaban versus warfarin. Using adjusted indirect
comparisons, there was signiﬁcant heterogeneity in results.
Dabigatran lowered the composite of systemic emboli or
Table 2 Results of Large RCTs of New Anticoagulants Versus Warfarin
Clinical Events and RCTs Novel Drug and Dose Novel Agent (%/yr) Warfarin (%/yr) HR (95% CI) p Value
Stroke or systemic embolism
RE-LY Dabigatran 110 mg twice daily 1.53 1.69 0.91 (0.74–1.11) 0.34
Dabigatran 150 mg twice daily 1.11 1.69 0.66 (0.53–0.82) <0.001
ROCKET-AF Rivaroxaban 20 mg daily 2.12 2.42 0.88 (0.75–1.03) 0.12
ARISTOTLE Apixaban 5 mg twice daily 1.27 1.60 0.79 (0.66–0.95) 0.01
Hemorrhagic stroke
RE-LY Dabigatran 110 mg twice daily 0.12 0.38 0.31 (0.17–0.56) <0.001
Dabigatran 150 mg twice daily 0.10 0.38 0.26 (0.14–0.49) <0.001
ROCKET-AF Rivaroxaban 20 mg daily 0.26 0.44 0.59 (0.37–0.93) 0.02
ARISTOTLE Apixaban 5 mg twice daily 0.24 0.47 0.51 (0.35–0.75) <0.001
Major bleeding
RE-LY Dabigatran 110 mg twice daily 2.71 3.36 0.80 (0.69–0.93) 0.003
Dabigatran 150 mg twice daily 3.11 3.36 0.93 (0.81–1.07) 0.31
ROCKET-AF Rivaroxaban 20 mg daily 3.60 3.45 1.04 (0.90–1.20) 0.58
ARISTOTLE Apixaban 5 mg twice daily 2.13 3.09 0.69 (0.60–0.80) <0.001
Death
RE-LY Dabigatran 110 mg twice daily 3.75 4.13 0.91 (0.80–1.03) 0.13
Dabigatran 150 mg twice daily 3.64 4.13 0.88 (0.77–1.00) 0.051
ROCKET-AF Rivaroxaban 20 mg daily 4.5 4.9 0.92 (0.82–1.03) 0.15
ARISTOTLE Apixaban 5 mg twice daily 3.52 3.94 0.89 (0.80–0.998) 0.047
The RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) trial (36) included 18,113 patients with AF. Two doses of dabigatran were compared with open-label warfarin with both safety and
efﬁcacy endpoints. ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) (41)
randomized 14,264 patients with nonvalvular AF at increased risk for stroke to either rivaroxaban or dose-adjusted warfarin. Both safety and efﬁcacy endpoints as noted were assessed. The ARISTOTLE
(Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (42) randomized 18,201 patients with AF and a greater or equal additional risk factor for stroke to apixaban or
warfarin. As per the other studies of novel oral anticoagulants, both safety and efﬁcacy endpoints were assessed as noted. Modiﬁed with permission from Granger and Armaganijan (39).
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; HR ¼ hazard ratio; RCT ¼ randomized clinical trial.
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293stroke versus rivaroxaban, and apixaban versus both rivar-
oxaban and dabigatran lowered the risk of major gastroin-
testinal bleeding. Of interest, in terms of gastrointestinal
bleeding, not all studies documented less bleeding than with
warfarin use. There was increased gastrointestinal bleeding
with dabigatran and rivaroxaban in the RE-LY (Random-
ized Evaluation of Long-Term Anticoagulant Therapy) trial
(36) and the ROCKET-AF (Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation) (41) but not with apixaban in the
ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) trial (42).
Device therapy. Given that the LAA has been found to be
the nidus of thrombus, resulting in stroke in approximately
90% of cases, approaches aimed at occlusion continue to be
explored (45–54). Although intuitively attractive, evaluation
of this strategy has proven difﬁcult. In contrast to the
multitude of large pharmaceutical trials that have random-
ized over 50,000 patients to either warfarin or an NOAC,
only a single randomized trial of an LAA occlusion device
has been published, and it included approximately 800
patients randomized in a 2:1 fashion device to warfarin (47).
Device evaluation has been difﬁcult because any device
strategy for occlusion of the LAA necessarily includes an
invasive procedure with its inherent attendant up-front
procedural risks compared with initiating drug therapy
alone. Furthermore, blinding common with pharmaceuticaltrials is very challenging with device trials. The PROTECTAF
(Watchman Left Atrial Appendage System for Embolic
Protection in Patients With Atrial Fibrillation) trial, which
compared the Watchman (Boston Scientiﬁc, Natick,
Massachusetts) LAA occlusion device to warfarin, identiﬁed
an early safety hazard mainly related to procedural pericar-
dial effusion occurring in approximately 5% of patients.
Although the pericardial effusion did not result in either
mortality or longer-term disability, it did prolong hospital
stay and was considered a serious adverse event. Other
procedural risks that occur with devices but not with initi-
ation of pharmacologic therapy include anesthetic-related
and peripheral vascular complications, as well as early
embolic events. Although device embolization is an obvious
risk, it is extremely rare. In addition, the long-term impli-
cations of leaving a permanent implant and the risk of
erosion are largely unknown. In small trials, such events and
concerns represent important imbalances in comparing
strategies. Another important issue relates to the fact that
some patients randomized to the device continue to also
receive anticoagulant therapy longer term either for a new
medical problem, such as the development of pulmonary
emboli, or for a residual leak around the device at the LAA
ostium, thereby making it difﬁcult to attribute any reduction
in stroke solely to the device itself. Peridevice leaks probably
related to variations in the anatomy, device-LAA ostial
mismatch, and heterogeneous remodeling of the LAA
tissues around the device remain a potential issue. They have
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as percutaneous LAA closure in the PROTECT AF trial. In
PROTECT AF, high-ﬂow narrow leaks were not asso-
ciated with increased risk of systemic thromboembolism
(53); however, the speciﬁc size of a peridevice leak that
might increase complications remains unclear. Impro-
vements in implantation-guided imaging, for example, with
3-dimensional transesophageal echocardiography or new
device iterations, might help to decrease this issue.
The PROTECT AF trial demonstrated that device place-
ment was noninferior to warfarin for the primary efﬁcacy
endpoint of stroke (either ischemic or hemorrhagic), cardio-
vascular death, or systemic thromboembolism using a non-
inferiority margin of 2. This noninferiority ﬁnding was offset
by the increase in adverse safety events in the device group, the
majority ofwhich occurredwithin theﬁrst 7 days.Longer-term
information on safety of theWatchman has become available.
This data combines information from thePROTECTAFtrial
with the CAP (Continued Access Protocol) registry (48). In
these 2 studies, 542 patients had been treated in PROTECT
AF and 460 in CAP. There was a signiﬁcant decrease in
procedure- or device-related safety events. The rate of serious
pericardial effusion decreased from 5.0% inPROTECTAF to
2.2% (p¼ 0.019) in the CAP registry, whereas periprocedural
stroke decreased from 0.9% to 0% (p ¼ 0.039). There was
also a reduction in safety events from the ﬁrst one-half of
enrollment in the PROTECT AF trial to the second one-
half, reﬂecting among other things, improved operator
experience and technique (48). The most recent data eval-
uates outcomes out to 2.3  1.1 years (Table 3). At this
time, the primary efﬁcacy event rates with the device
remained noninferior to warfarin control: 3.0% per 100
patient-years with device versus 4.3% in the control group
(rate ratio [RR]: 0.71, 95% conﬁdence interval [CI]: 0.44%
to 1.30% per year). The effect was similar across multiple
pre-deﬁned subsets (Fig. 1). The previously mentioned early
safety hazard related to periprocedural events, though
improved, was still higher with device placement (50).
The outcome of PROTECT AF has now been reported,
and the ﬁndings and conclusions have changed signiﬁcantly.Table 3 Efﬁcacy and Safety Results at 2.3-Year Follow-Up of the PR
Device
Events/Pt-Yrs OR/100 Pt-Yrs (95% CI) Events/Pt-Yr
Primary efﬁcacy 31/1,025.7 3.0 (2.1–4.3) 24/562.7
Ischemic stroke 19/1,026.3 1.9 (1.1–2.9) 8/564.9
CV/unexplained
death
11/1,050.4 1.0 (0.5–1.8) 16/573.2
Hemorrhagic stroke 3/1,050.3 0.3 (0.1–0.7) 7/571.0
Systemic embolism 3/1,049.8 0.3 (0.1–0.7) 0/573.2
All stroke 21/1,026.3 2.0 (1.3–3.1) 15/562.7
All-cause mortality 34/1,050.4 3.2 (2.3–4.5) 26/573.2
Primary safety 54/979.9 5.5 (4.2–7.1) 2/554.6
Endpoint data in the PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in P
noninferior to warfarin. *Rate ratio (RR) (intervention/control). Modiﬁed with permission from Reddy et
CI ¼ conﬁdence interval; CV ¼ cardiovascular; OR ¼ odds ratio; Pt-yrs ¼ patient-years; d ¼ data notA total of 707 patients had a mean follow-up of 45 months,
and, in aggregate, 2,621 patient-years. Superiority criteria for
the composite efﬁcacy endpoint were now achieved. Using the
Cox proportional hazards model, there were 2.3 events per
100 patient-years in the Watchman group versus 3.8 in the
warfarin group (hazard ratio: 0.61, 95% CI: 0.38 to 0.97; p¼
0.0348). There were fewer fatal or disabling strokes in the
device group (RR: 0.37). The efﬁcacy results were consistent
across subgroups based on age, sex, CHADS2 score, and
previous warfarin use. In this ﬁnal analysis, the composite
primary safety events between the 2 groups were now non-
inferior (RR: 1.17, 95% credible interval: 0.78 to 1.95).
A second randomized pivotal trial has now been
completed (PREVAIL [Evaluation of the Watchman LAA
Closure Device in Patients With Atrial Fibrillation Versus
Long Term Warfarin Therapy]; NCT01182441) that aimed
at documenting continued improved safety and at conﬁrm-
ing the efﬁcacy demonstrated in the PROTECT AF trial.
Current issues compromising the implementation of
procedural approaches for stroke prevention in AF are dis-
cussed herein and include: 1) lack of multiple randomized
clinical trials; 2) lack of consensus regarding the appropriate
target population to study; and 3) ability to obtain approval
of devices for outcome measures of unconﬁrmed clinical
importance, such as, the use of complete closure of the LAA
at the time of the index procedure as a surrogate for clinical
efﬁcacy.
Randomized Clinical Trials and Target Populations
As previously mentioned, there is only a single randomized
clinical trial of percutaneous closure that has been completed
and published (47). The major criticisms of this initial
pivotal trial include the following: small sample size
compared with the pharmacologic trials in similar patient
groups; a mean CHADS2 score of 2.2  1.2; the boundaries
of noninferiority; the initial use of 45 days of warfarin in the
device group, which was designed to enhance endotheliali-
zation but also possibly contributed to improved early
outcome in the device group or alternatively improved safetyOTECT-AF Trial
Control Posterior Probabilities
s OR/100 Pt-Yrs (95% CI) RR* (95% CI) Noninferior Superior
4.3 (2.6–5.9) 0.71 (0.44–1.30) >0.99 0.88
1.4 (0.6–2.4) 1.30 (0.66–3.60) 0.76 0.18
2.8 (1.5–4.2) 0.38 (0.18–0.85) >0.99 0.99
1.2 (0.5–2.3) 0.23 (0.04–0.79) >0.99 0.99
0 d d d
2.7 (1.5–4.1) 0.77 (0.42–1.62) >0.99 0.73
4.5 (2.8–6.2) 0.71 (0.46–1.28) >0.99 0.85
3.6 (2.2–5.3) 0.53 (0.95–2.70) d d
atients With Atrial Fibrillation) trial at 2.3-year follow-up. The composite primary endpoint remains
al. (50).
available.
Figure 1 Percutaneous LAA Closure for Stroke Prophylaxis
Follow-up at 2.3 years of the PROTECT AF trial. Reproduced with permission from Reddy et al. (50). AF ¼ atrial ﬁbrillation; CHADS2 ¼ congestive heart failure, hypertension,
age 75 years, diabetes mellitus, stroke/transient ischemic attack score; LAA ¼ left atrial appendage; LVEF ¼ left ventricular ejection fraction; PROTECT AF ¼ Watchman Left
Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation trial.
JACC Vol. 63, No. 4, 2014 Holmes, Jr., et al.
February 4, 2014:291–8 Device and Regulatory Issues in Developing LAA Occlusion
295risks; the reintroduction of warfarin later during the follow-
up period for other reasons; restricting the trial to patients
who were candidates for warfarin; time in therapeutic range
in the warfarin arm; and inclusion of both ischemic and
hemorrhagic strokes as an efﬁcacy endpoint. An additional
important limitation is the restriction of the anticoagulant
only to warfarin, thereby excluding the NOACs.
An important consideration to be addressed in this regard
is the need for a randomized trial in a patient population not
treated with anticoagulants. The current and planned
randomized clinical trials have as their focus patients who are
candidates for oral anticoagulant therapy either warfarin or
an NOAC. This excludes approximately 50% of patients
who are at risk for stroke but are not felt to be candidates for
oral anticoagulants. Such candidates are at increased risk for
complications; approval of a device in this group would add
an important alternative therapeutic strategy. There are
problems with the design of such a trial in terms of deﬁni-
tion of criteria for “an absolute or relative contraindication to
oral anticoagulants,” as well as the speciﬁc treatment in the
control groupdeither aspirin alone or dual antiplatelet
therapy, neither of which has been proven effective for stroke
prevention. The closest data available in patients who were
not candidates for warfarin include the Watchman (ASAP
[ASA Plavix Feasibility Study With Watchman Left Atrial
Appendage Closure Technology]) registry (54) of 150
patients in whom the device was implanted. Patients were
treated only with either aspirin or dual antiplatelet therapy,
despite the fact that acetylsalicylic acid and clopidogrel
might also be associated with increased bleeding similar to
warfarin. In this trial, patients had a mean CHADS2 score
of 2.8, which would predict an event rate of approximately
7%; in contrast to what was expected, stroke and transientischemic attack occurred in only 1.7%, a reduction of
approximately 75%. Although statistically underpowered for
clinical events, the ASAP registry offers data that might
affect patient care and outcome.
A current randomized clinical trial, the ACP (Amplatzer
Cardiac Plug Clinical Trial; NCT01118299) (Amplatzer,
St. Jude Medical, St. Paul, Minnesota), which has taken
approximately 1 year for investigational device exemption
approval, has been affected greatly with changes in inclu-
sion/exclusion criteria as well as in endpoints. For example,
either current or anticipated use of any thienopyridine is
a contraindication for participation. Whereas the inclusion
of patients taking a thienopyridine could introduce con-
founding bias, making interpretation of results difﬁcult, the
current selection criteria exclude patients who might beneﬁt
the most: those with a need for dual antiplatelet therapy, for
example, patients with drug-eluting stents in addition to oral
anticoagulation for stroke prevention who are at a greatly
increased risk for hemorrhage. This study will include
control patients on dabigatran.
Alternative Devices
A ﬁnal related issue comes after approval of a single device in
a new category of devices. Do subsequent trials of either new
iterations of the initial devices or new designs have to be
randomized against the initial device (Watchman) or against
the control group in the initial protocol trials (warfarin)? The
approval of devices currently used for LAA occlusion but
only approved for nonstroke prevention indications is
problematic (52). The prototypical device in this category is
the Lariat device (SentreHEART, Inc., Redwood City,
California), which received 510(k) approval for opposing
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external transpericardial approach to occlude the LAA by
a suture. Both transvenous and direct pericardial access are
required. Magnetically-tipped guidewires are positioned to
meet at the tip of the dominant lobe of the LAA. A suture
fashioned as a “lasso or lariat” is positioned over the peri-
cardial access wire and then tightened to occlude the LAA.
The largest series of Lariat cases reported to date is 85
patients, so information sufﬁcient to evaluate device and pro-
cedure safety and effectiveness is very limited (52). Although
eligibility criteria included “a poor candidate or ineligible for
warfarin,” at 1-year follow-up (52), 55% of patients were
receiving warfarin. The rate of closure of the appendage with
this device was approximately 95%. Even though closure
documented on transesophageal echocardiograms with this
particular device is very compelling, closure alone has not
been validated as a surrogate for stroke prevention and should
not be used as such. Pericarditis, which can be quite severe
and anecdotally appears to occur with some frequency,
typically results in prolongation of the initial hospital stay.
Whether severe pericarditis will have lasting sequelae remains
unknown. Although this approach looks promising, in
the absence of controlled scientiﬁc data, very limited
conclusions can be drawn.
Exclusion of the LAA can also be performed at the time
of concomitant cardiac surgery. Currently-available surgical
methods to isolate the LAA include: 1) suture ligation; 2)
excision and suture closure; and 3) stapling exclusion with or
without excision. These techniques remain limited by issues
of incomplete closure and residual ﬂow in up to one-third of
patients (55,56) and trauma to the appendage.
New devices for surgical approaches have been devel-
oped. The Atriclip Device System (Atricure, Inc., West
Chester, Ohio), a self-closing, sterile, implantable clip with
a reusable deployment tool, is applied epicardially by either
an open surgical or a minimally-invasive technique and is
available in 4 sizes (35, 40, 45, and 50 mm). In the
European trial that led to CE mark approval, 34 patients
underwent successful clip placement; there were no device-
related complications (57). LAA occlusion was conﬁrmed
by intraoperative transesophageal echocardiography and
by serial computed tomography at 3 months in all patients.
In the U.S. regulatory trial of the same device, 71 patients
undergoing open cardiac surgery at 7 U.S. centers were
enrolled (58). In 1 patient, the LAA was too small and did
not meet eligibility criteria; the remaining 70 patients
had successful placement of the device. Intraprocedural
successful exclusion was conﬁrmed in 67 of 70 patients
(95.7%). There were no adverse events related to the
device, and at 3 months, 60 of 61 patients (98.4%) who
underwent imaging had successful LAA exclusion by
computed tomography angiography or transesophageal
echocardiography.
The Tiger Paw System (Terumo Cardiovascular Systems,
Ann Arbor, Michigan) is another device approved for
commercial use in the United States (59). In the regulatorystudy, 60 patients were enrolled. Transesophageal echocar-
diograms at 90 days were available in 54 patients, and no leaks
were detected.
Summary and Recommendations
The issues of stroke prevention in patients with AF are
extremely important. Although there is an abundant dataset
on the use of warfarin and now new anticoagulant strategies,
many problems remaindfor example, long-term chronic
therapy, incremental lifetime risk of bleeding, cost, and
drug-drug interactionsdas well as the fact that approxi-
mately 50% of patients at risk are not treated with these
agents. With the increasing data that occlusion of the LAA
results in an outcome that is at least noninferior and is now
documented to be superior to warfarin, what can be done
to enhance regulatory approval of these devices? The answer
is continued data with well-controlled efﬁcient studies
adequately powered with important clinical endpoints in
multiple groups of patients who could beneﬁt.
One option would be to expedite the approval of LAA
occlusion devices once they have passed the regulatory safety
tests and to subsequently demonstrate efﬁcacy as compared
with currently effective anticoagulants. This could be
accomplished by combining well-conducted randomized
clinical trials with rigorous post-marketing registries that
include standardized data forms, detailed inclusion criteria,
procedural outcome, and clinical follow-up focusing on
stroke events and bleeding. The TVT (Transcatheter Valve
Therapy) registry (60) for post-market surveillance of
transcatheter aortic valve replacement is an example of such
a registry. A similar registry could be initiated by the
professional societies that focus on LAA occlusion devices.
These registries should include monitoring and rigorous
surveillance up to 5 years to establish the knowledge of the
risks and beneﬁts of such devices for a broad study pop-
ulation. Although post-market surveillance studies have
their own set of issues, such as relying on site-reported
outcomes and limited complete rigorous monitoring, the
data generated will serve as a guide for physicians to tailor
the optimal therapy for the treatment of nonvalvular AF.
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